SureTrader Advertisement PRTC
Home > Boards > Free Zone > Health and Sciences > Biotech Values

>AVEOwhether they would rather focus on other indications

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
biomaven0 Member Profile
Member Level 
Followed By 75
Posts 4,366
Boards Moderated 0
Alias Born 02/27/07
160x600 placeholder
Civil Antitrust Suits Reinstated Against Banks In Libor Case
In a setback for some the world's largest financial institutions, a U.S. appeals court reinstated private antitrust lawsuits filed against 16 banks for allegedly rigging Libor interest rates.
More Top Equities Stories Of The Day
Bayer Lays Out Offer for Monsanto -- WSJ
Court Tosses Crisis-Era Fraud Fine -- WSJ
Shanda Group Accumulates 11.7% LendingClub Stake
Facebook Shifts Topics Feature Amid Bias Fears--update
Comcast Sued by Viamedia for Monopolization of 'Spot' Cable Ad Sales Market
Samsung Targets U.S. Drug Market With Remicade Knockoff
GE Sets $1 Billion in Saudi Projects -- WSJ
Nokia to Return to Cellphones Via Licensing Pact -- Update
biomaven0 Member Level  Thursday, 09/08/11 09:41:43 AM
Re: NP1986 post# 126293
Post # of 201545 
>AVEO

Quote:
whether they would rather focus on other indications



My guess is they will try to go for combination therapy - any place where Avastin has shown good results in combination would be a good place to start.

In terms of going up against Sutent vs. against Nexavar, it's somewhat instructive that Pfizer made the same choice in 2nd line for their drug. I'm of the view that a small company should almost always take the easiest path to registration - worry about expanding the market once you have approval.

Peter

SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist